Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06223269 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

A Phase 3 study of Wound Heal and Burns Degree Third, sponsored by XenoTherapeutics.

Recruiting
Registry status
Phase 3
Development phase
50
Enrollment target
4
Study locations

NCT06223269: Recruiting Phase 3 study of Wound Heal and Burns Degree Third, sponsored by XenoTherapeutics.

NCT06223269 is a Phase 3 study of Wound Heal and Burns Degree Third that is actively recruiting participants, run by XenoTherapeutics. The registered enrollment target is 50 participants, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06223269, a Phase 3 study of Wound Heal and Burns Degree Third, is actively recruiting participants, sponsored by XenoTherapeutics.

RECRUITING
Registry status
Phase 3
Development phase
50 participants
Enrollment target
4
Study locations

Study Summary

To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.

Primary Outcome

Complete wound closure is defined as \>95% skin re-epithelization in an area of the treatment site without drainage or dressing requirements by Post-Treatment Day 28 (± 7 days). Durable wound closure is defined as confirmation of complete wound closure in an area of the treatment site at two consecutive evaluations, spaced by no less than 14 days and no more than 5 months. Post-Treatment is defined as time elapsed following autografting and treatment with realSKIN, and is not necessarily time

Interventions

  • DRUG Skin Xenotransplant
  • PROCEDURE Autograft(ing)

Study Locations (4)

Arizona

  • Arizona Burn Center Valleywise Health - Phoenix

Georgia

  • JMS Burn Center at Doctors Hospital - Augusta

Maine

  • MaineHealth Maine Medical Center - Portland

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-05-09
Est. Completion 2026-01
Phase Phase 3
XenoTherapeutics

2 total trials

What NCT06223269 shows while recruiting

NCT06223269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (58% lower).

The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 2 interventions - of which Skin Xenotransplant is the first listed.

NCT06223269 reports a single indexed study location in Arizona, Georgia, Maine.

Frequently Asked Questions

What is clinical trial NCT06223269 about?

NCT06223269 is a clinical study titled "Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting". To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.

What is the current status of trial NCT06223269?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-05-09. Estimated completion is 2026-01.

What conditions does trial NCT06223269 study?

This clinical trial studies the following conditions: Wound Heal, Burns Degree Third, Burn (Disorder), Burn Degree Second, Thermal Burn.

What interventions are being tested in trial NCT06223269?

The interventions under investigation include: Skin Xenotransplant (DRUG), Autograft(ing) (PROCEDURE).

Who is sponsoring clinical trial NCT06223269?

This trial is sponsored by XenoTherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06223269 being conducted?

This trial has 4 study locations across Arizona, Georgia, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Heal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06223269's enrollment target sits among peer trials

50 13th of 23 higher than 9 of 23 other Wound Heal trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wound Heal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06223269, the US trial registry maintained by the National Library of Medicine. NCT06223269 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.